Urinary leukotriene E₄ levels in patients with atopic dermatitis

Abstract

Leukotriene synthesis may be increased in a variety of inflammatory diseases. Urinary leukotriene E4 is a stable metabolite of leukotrienes C4 and D4 which has previously been found to be increased in exacerbations of severe asthma and after antigen inhalation. Levels of urinary LTE4 in seven patients during and after a severe flare of atopic dermatitis were measured by high-performance liquid chromatography (HPLC) and radioimmunoassay (RIA). Mean urinary LTE4 levels (+/- SEM) were not increased during (16.7 +/- 3.7 pg/mumol) or after (16.9 +/- 4.8 mumol) the acute exacerbation of atopic dermatitis when compared with the normal range (mean = 23.8 [95% confidence interval 19.9-28.2] pg/mumol creatinine). These findings do not provide evidence of cysteine leukotriene involvement in the pathogenesis of atopic dermatitis.

Brief case series: Montelukast, at doses recommended for asthma treatment, reduces disease severity and increases soluble CD14 in children with atopic dermatitis

“…Four boys and three girls, with a median (range) age of 12 (3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16) years, participated in the study. Their median (range) SCORAD scores before and after treatment were 34.7 (16.5-54.8) and 17.0 (6.9-36.9) (Figure 1; pv0.05).…”

“…Indeed, activated circulating basophils from these patients have increased the releasability of LTC 4 [10]. The elevated urinary concentration of LTE 4 , a stable metabolite of LTC 4 and LTD 4 , and being a useful index of whole-body cysteinyl LT production in vivo [11], have been reported in patients with AD [12][13][14]. In a recent study of 126 children with AD [15], we also found significant correlations between the urinary LTE 4 concentration and overall SCORAD score (r50.270, p50.002), its extent (r50.185, p50.038) and intensity components (r50.247, p50.005).…”

The role of leukotrienes in allergic diseases

“…Several studies report increased levels of LTE 4 in the urine of AD patients, which are associated with disease exacerbation. 191,192 High LTC 4 levels are detected in extracts from skin lesions and in the serum of AD patients, and levels decrease as the disease becomes less severe. 193 Despite the fact that LTRAs are generally recommended for asthma patients with moderate to severe AD, 194 one clinical study reported that treating AD patients with montelukast had no beneficial effect compared with a placebo.…”

Efficacy and Tolerability of Montelukast as a Therapeutic Agent for Severe Atopic Dermatitis in Adults

“…Comparison between t0 and t2 (time of treatment at baseline and end of the study) was evaluated with Student's t-test for unpaired samples. healthy individuals (9). Eosinophilic in ltration of AD 3.…”